论文部分内容阅读
目的探讨替比夫定片对慢性乙肝患者细胞免疫功能的影响。方法选取西安市北方医院2014年1月—2015年5月收治的慢性乙肝患者126例,根据随机数字表法分为治疗组与对照组各63例,对照组口服恩替卡韦治疗,治疗组口服替比夫定治疗,治疗观察周期为3个月。结果治疗后治疗组的HBV DNA转阴率和HBe Ag阴转率分别为95.2%和71.4%,对照组为81.0%和44.4%,组间对比差异均有统计学意义(P<0.05)。治疗后治疗组与对照组的ALT值分别为(46.09±15.98)U/L和(76.13±19.55)U/L,都明显低于治疗前的(153.20±33.01)U/L和(151.30±26.02)U/L(P<0.05),且治疗组降低程度更多,与对照组比较差异明显(P<0.05)。两组治疗后的血清IL-2值明显上升(P<0.05),而IL-4值明显降低(P<0.05),同时治疗后治疗组的血清IL-2与IL-4值与对照组相比差异也有统计学意义(P<0.05)。治疗后治疗组与对照组的血CD4~+CD25~+值分别为(2.22±1.02)%和(3.45±0.98)%,都明显低于治疗前的(4.87±1.22)%和(4.89±1.02)%(P<0.05),同时组间对比差异明显(P<0.05)。结论替比夫定片治疗慢性乙肝患者能有效提高机体细胞免疫功能,降低血清炎症因子的表达,有利于抑制乙肝病毒的复制与肝功能的恢复,有很好的应用价值。
Objective To investigate the effect of telbivudine on cellular immune function in patients with chronic hepatitis B Methods A total of 126 patients with chronic hepatitis B admitted to the Northern Hospital of Xi’an from January 2014 to May 2015 were randomly divided into treatment group (63 cases) and control group (63 cases). The control group was treated with entecavir, Fuding treatment, treatment observation period of 3 months. Results After treatment, the rates of HBV DNA negative conversion and HBeAg negative conversion were 95.2% and 71.4% in the treatment group and 81.0% and 44.4% in the control group, respectively. The difference between the two groups was statistically significant (P <0.05). After treatment, the ALT values of the treatment group and the control group were (46.09 ± 15.98) U / L and (76.13 ± 19.55) U / L respectively, which were significantly lower than those before treatment (153.20 ± 33.01 U / L and 151.30 ± 26.02 ) U / L (P <0.05), and the treatment group decreased more significantly compared with the control group (P <0.05). After treatment, serum IL-2 level increased significantly (P <0.05) and IL-4 level decreased significantly (P <0.05). After treatment, the serum IL-2 and IL-4 levels in the treatment group were significantly lower than those in the control group The difference was also statistically significant (P <0.05). The values of CD4 ~ + CD25 ~ + in the treated group and the control group after treatment were (2.22 ± 1.02)% and (3.45 ± 0.98)%, respectively, which were significantly lower than those before treatment (4.87 ± 1.22)% and (4.89 ± 1.02) )% (P <0.05), meanwhile there was significant difference between the two groups (P <0.05). Conclusion The treatment of chronic hepatitis B patients with telbivudine tablets can effectively improve the cellular immune function, reduce the expression of serum inflammatory cytokines, is beneficial to inhibit the replication of hepatitis B virus and the recovery of liver function, and has a good application value.